報價延遲最少15分鐘:2025/01/21 18:40 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.805 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.33/-0.49
|
|
企業價值
88.25M
|
| 資產負債 |
|
每股賬面淨值
-0.96
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
56.83M
|
|
每股收益
2.63
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 18:40 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment. |